Question: Which American global medical device company is headquartered in Little Canada, Minnesota?

Context articles: Global Medical Device Nomenclature
Mauna Kea Technologies
Alvimedica
Stephen P. MacMillan
Hospira
St. Jude Medical
Marion Greene
Mölnlycke Health Care
Global Harmonization Task Force
MetaCure

Global Medical Device Nomenclature (GMDN) is a system of internationally agreed generic descriptors used to identify all medical device products.
 This nomenclature is a naming system for products which include those used for the diagnosis, prevention, monitoring, treatment or alleviation of disease or injury in humans.
Mauna Kea Technologies is a global medical device company focused on leading innovation in endomicroscopy, the field of microscopic imaging during endoscopy procedures.
 The company researches, develops and markets tools to visualize, detect and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
Alvimedica is a manufacturer of coronary stents, balloon catheters, diagnostic and guiding catheters.
 The company was founded in 2007 by Turkish businessmen and scientists living in Denmark and Sweden.
 The major intention of the company is investing in small and medium size medical device manufacturers to enable them to compete globally.
 The company made its first investment move by purchasing a medical device company called Nemed in Turkey in 2007.
 Following this, the company purchased an American company called In-Vivo, a manufacturer of angioplasty and angiography catheters, and one of the suppliers of Abbott Laboratories.
Stephen P. MacMillan is the Chairman, President, and Chief Executive Officer, and Director of Hologic, a medical device and diagnostic manufacturer headquartered in Marlborough, Massachusetts.
 He was previously the Chairman of the Board, President, and Chief Executive Officer of Stryker Corporation, a global medical device company, and has 24 years of healthcare industry operating experience.
 He served as Chief Executive Officer of Stryker from January 2005 to February 2012 and served as its President from June 2003 to February 2012.
 During his tenure at Stryker, MacMillan successfully led the company through a series of key strategic acquisitions, the launch of a number of products within the orthopedic implants and medical instrumentation businesses, and delivered strong operating performance, with revenue growing from $2.8 billion to $8.3 billion, between 2003 and 2011.
 During his tenure, Stryker delivered stock price appreciation of more than 62%, compared to appreciation of the S&P 500 index of approximately 40%.
 While MacMillan presided as CEO, Stryker was selected by FORTUNE, over multiple consecutive years, as one of the "World's Most Admired Companies" in the Medical Equipment Industry.
Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois.
 It had approximately 15,000 employees.
 Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems.
 Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.
 It was formerly the hospital products division of Abbott Laboratories.
 On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.
St. Jude Medical, Inc. was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul.
 The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries.
 Its major markets include the United States, Europe, Latin America and Asia-Pacific.
 The company was named after Jude the Apostle, the patron saint of lost causes.
Marion C. Greene (born July 16, 1970) is a Hennepin County commissioner (District 3) and a former member of the Minnesota House of Representatives who represented District 60A, which included portions of the city of Minneapolis in Hennepin County, which is in the Twin Cities metropolitan area.
 A Democrat, she was a health policy analyst for St. Jude Medical in Little Canada.
Mölnlycke Health Care is a Swedish medical device company headquartered in Gothenburg and active internationally.
 The company manufactures and sells wound care and single-use surgical products and is a service provider to the healthcare sector.
 The surgical division includes medical devices such as drapes, gowns, facemasks, and headwear.
 The wound care division includes medical device wound healing solutions such as dressings, compression products and skin care products and emollients.
 Featured products in wound care include those with Safetac® technology available exclusively on Mepitel® , Mepilex® , and other dressings.
 The wound care product assortment also includes WoundEL® electrostimulation for hard-to-heal wounds, wound dressings such as Mepore® , compression bandages, dermatology products and retention products such as Tubifast®.
The Global Harmonization Task Force (GHTF) was “a voluntary group of representatives from national medical device regulatory authorities (such as the U.S. Food and Drug Administration (FDA)) and the members of the medical device industry” whose goal was the standardization of medical device regulation across the world.
 The representatives from its five founding members (the European Union, the United States, Canada, Japan and Australia) were divided into three geographical areas: Europe, Asia-Pacific and North America, each of which actively regulates medical devices using their own unique regulatory framework.
 Founded in 1992, the GHTF was created in “an effort to respond to the growing need for international harmonization in the regulation of medical devices."
MetaCure is a privately held global medical device company that develops and markets minimally invasive treatments for type 2 Diabetes and obesity by regulating postprandial sugar metabolism and satiety through the use of gastric electrical stimulation.